Linked Data API

Show Search Form

Search Results

1124902
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15577 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15576 more like this
star this property question first answered
less than 2019-05-17T11:07:46.673Zmore like thismore than 2019-05-17T11:07:46.673Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1127500
star this property registered interest false more like this
star this property date less than 2019-05-20more like thismore than 2019-05-20
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019. more like this
star this property tabling member constituency West Lancashire more like this
star this property tabling member printed
Rosie Cooper more like this
star this property uin 256255 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-05-29more like thismore than 2019-05-29
star this property answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 256254 more like this
star this property question first answered
less than 2019-05-29T10:38:01.217Zmore like thismore than 2019-05-29T10:38:01.217Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1538
star this property label Biography information for Rosie Cooper more like this
1126022
star this property registered interest false more like this
star this property date less than 2019-05-13more like thismore than 2019-05-13
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will expedite the process by which the NICE publishes its decisions. more like this
star this property tabling member constituency Stroud more like this
star this property tabling member printed
Dr David Drew more like this
star this property uin 253483 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-05-21more like thismore than 2019-05-21
star this property answer text <p>The Government wants patients to be able to benefit from access to effective new treatments as quickly as possible.</p><p>Through its technology appraisal and highly specialised technologies guidance, the National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations on whether medicines and other treatments represent a clinically and cost effective use of National Health Service resources. NHS organisations are legally required to make funding available for NICE recommended treatments, usually within three months of final guidance.</p><p>Wherever possible, NICE currently aims to publish recommendations on new drugs as soon as possible after licensing, with draft guidance on cancer drugs published in advance of licensing. The 2019 Voluntary Scheme for Branded Medicines Pricing and Access includes a commitment to faster NICE assessments of new medicines, with timelines for non-cancer drugs to match those for cancer drugs, subject to the evidence base for the product being sufficiently developed.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-21T10:58:38.627Zmore like thismore than 2019-05-21T10:58:38.627Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
252
star this property label Biography information for Dr David Drew more like this
1131740
star this property registered interest false more like this
star this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, which topics have been identified for inclusion in the upcoming review of the appraisal methods used by NICE. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263870 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
263871 more like this
263872 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.087Zmore like thismore than 2019-06-20T13:18:08.087Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
star this property label Biography information for Daniel Zeichner more like this
1131742
star this property registered interest false more like this
star this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the timescale is for NICE's Methods review. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263871 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
263870 more like this
263872 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.15Zmore like thismore than 2019-06-20T13:18:08.15Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
star this property label Biography information for Daniel Zeichner more like this
1131743
star this property registered interest false more like this
star this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether changes to NICE’s appraisal methods identified during the NICE Methods review will be cost-neutral. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263872 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
263870 more like this
263871 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.213Zmore like thismore than 2019-06-20T13:18:08.213Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
star this property label Biography information for Daniel Zeichner more like this
1131744
star this property registered interest false more like this
star this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what criteria was used by NICE to determine which patient organisations were offered membership of the NICE Methods Working Group. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263873 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
263870 more like this
263871 more like this
263872 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.26Zmore like thismore than 2019-06-20T13:18:08.26Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
star this property label Biography information for Daniel Zeichner more like this
1131746
star this property registered interest false more like this
star this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what opportunities there will be for patient groups that are not part of the NICE Methods Working Group to take part in the task and finish groups. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263874 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
263870 more like this
263871 more like this
263872 more like this
263873 more like this
star this property question first answered
less than 2019-06-20T13:18:08.323Zmore like thismore than 2019-06-20T13:18:08.323Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
star this property label Biography information for Daniel Zeichner more like this
1129860
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the timescale is for the planned methods and processes review of the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency West Ham more like this
star this property tabling member printed
Lyn Brown more like this
star this property uin 259921 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-12more like thismore than 2019-06-12
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technology recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will be subject to a public consultation.</p><p> </p><p>NICE has established a working group consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s senior management team, which in turn will report to the NICE Board.</p><p> </p><p>NICE is in the process of scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations, with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipate being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
259922 more like this
259923 more like this
259924 more like this
star this property question first answered
less than 2019-06-12T16:31:07.383Zmore like thismore than 2019-06-12T16:31:07.383Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1583
star this property label Biography information for Lyn Brown more like this
1129861
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, who will lead the planned methods and processes review of the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency West Ham more like this
star this property tabling member printed
Lyn Brown more like this
star this property uin 259922 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-06-12more like thismore than 2019-06-12
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technology recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will be subject to a public consultation.</p><p> </p><p>NICE has established a working group consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s senior management team, which in turn will report to the NICE Board.</p><p> </p><p>NICE is in the process of scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations, with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipate being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
259921 more like this
259923 more like this
259924 more like this
star this property question first answered
less than 2019-06-12T16:31:07.507Zmore like thismore than 2019-06-12T16:31:07.507Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1583
star this property label Biography information for Lyn Brown more like this